Pentasubstituted Indolizines for Multi-Target Anti-TB Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tubercular drugs face challenges such as drug resistance, significant side effects, and limited efficacy against multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), and totally drug-resistant tuberculosis (TDR-TB), necessitating the development of novel compounds with multiple modes of action.
Innovation Solution
The development of 1,2,3,6,8-pentasubstituted indolizines with specific structural substitutions, which exhibit anti-tubercular activity by targeting the mycobacterial enoyl-ACP reductase (InhA) enzyme and potentially anthranilate phosphoribosyltransferase, offering a multi-targeting approach to combat MDR and XDR-TB strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-TB drugs are used, then initial treatment efficacy is achieved, but drug resistance develops and side effects occur
Solution Approach 1:
The patent applies poly-pharmacology by designing indolizine derivatives that can bind to multiple biological targets simultaneously. The compounds exhibit activity against MmpL3, MenA, MenG, and other MTB enzymes, allowing a single molecule to perform multiple anti-TB functions and reduce resistance development through multi-target inhibition
Solution Approach 2:
The patent uses composite chemical structures by combining the indolizine core scaffold with various substituent groups (R1-R6) to create molecules with enhanced and diversified biological activities. This structural composite approach enables the compounds to interact with multiple enzymatic targets while maintaining potency
2Device complexity
If single-target anti-TB drugs are used, then mechanism of action is simple, but resistance insurgence occurs
Solution Approach 1:
The indolizine derivatives are designed to inhibit multiple MTB enzymes including MmpL3 (pan-drug resistant TB), MenA (mycolic acid biosynthesis), and MenG (fatty acid biosynthesis). This multi-target approach prevents resistance insurgence by simultaneously blocking several essential bacterial pathways
3Object-affected harmful factors
If novel multi-targeting compounds are developed, then resistance and side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent optimizes the indolizine derivative structures by systematically varying substituent parameters (R1-R6 groups) to achieve the desired balance between multi-target activity and reduced toxicity. By adjusting molecular weight, lipophilicity, and functional group positioning, the compounds maintain efficacy while improving safety profiles
Data Source
AI summary
Anti-tubercular compounds include trisubstituted indolizines having the following structural formula:wherein R1 is selected from the group consisting of 4-OCH3, 4-Cl, 4-Br, 4-F, 2-NO2, 3,5-CF3, CN, CH3, R2 is COOCH3, COOC2H5, and R3 is H and COOCH3.